Josep Castellví Vives Institutions of which they are part Translational Molecular Pathology Vall Hebron Institut de Recerca Email Josep Castellví Vives Email Institutions of which they are part Translational Molecular Pathology Vall Hebron Institut de Recerca
Research lines Study of CAP-dependent and CAP-independent signalling pathways in breast carcinomas. In previous works we studied several factors involved in cell signalling pathways that control cell growth. The found that the phosphorylated form of 4E-BP1 was the only factor that correlated with prognosis, and histologic aggressive features in several types of cancers. 4E-BP1 is a key regulator of CAP-dependent traslation and its main function is the inactivation of eIF4E. However, not all the aggressive tumors show activation of this factor. On the other hand, it has been shown that under hypoxia conditions cells the translation of some key factors can be regulated by CAP-independent pathways, mediated by factors known as ITAFs. The aim of our study is to find the CAP-depdendent/CAP-independent balance in tumors in relation to hypoxia, and evaluate its impact on prognosis. IP: Josep Castellví Vives Projects Establecimiento de una estrategia combinada en carcinoma escamoso de cabeza y cuello (HNSCC): una herramienta eficaz para superar los tumores quimiorresistentes. IP: Matilde Lleonart Pajarin Collaborators: Yoelsis Garcia Mayea, Juan Lorente Guerrero, Josep Castellví Vives, Marina Bataller Fernández, Pablo Sanchez Sancho, Almudena Sanchez Garcia, Juan Fernando Fuentes Cabrera Funding agency: Instituto de Salud Carlos III Funding: 240000 Reference: PI24/00630 Duration: 01/01/2025 - 31/12/2027 NANORESCAN IP: Matilde Lleonart Pajarin Collaborators: David Virós Porcuna, Josep Castellví Vives, Marina Bataller Fernández, Almudena Sanchez Garcia, Juan Fernando Fuentes Cabrera Funding agency: Instituto de Salud Carlos III Funding: 318750 Reference: AC24/00057 Duration: 01/01/2025 - 31/12/2027 ScreenEC, validació d'una eina de triatge no invasiu en càncer d'endometri IP: Eva Colas Ortega Collaborators: Vicente Bebia Conesa, Francesc Xavier Serra Marin, Josep Castellví Vives, Silvia Cabrera Diaz, Antonio Gil Moreno, Marta Rebull Santamaria, Ana Luzarraga Aznar, Irene De la Calle Fuentes, Lourdes Elena Salazar Huayna, Lourdes Elena Salazar Huayna Funding agency: Generalitat de Catalunya - Departament de Salut Funding: 99946 Reference: SLT036/24/000059 Duration: 21/12/2024 - 20/12/2025 inhibición de la comunicación celular para la prevención del desarrollo de metástasis y la resistencia a terapias antitumorales. Desarrollo de dos nuevas aproximaciones terapéuticas IP: Santiago Ramon y Cajal Agüeras Collaborators: Maria Rosa Somoza Lopez de Haro, Josep Castellví Vives, Sara Garcia Ortega, Elena Muro Blanc, Marta Cano Galietero, Javier Hernandez Losa, Marta Sese Faustino, Stefan Hummer, Lourdes Elena Salazar Huayna, Lourdes Elena Salazar Huayna Funding agency: Instituto de Salud Carlos III Funding: 240000 Reference: PI23/01754 Duration: 01/01/2024 - 31/12/2026 Pagination Current page 1 Page 2 Page 3 Page 4 Page 5 … Next page › Last page »
